U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Chromosome 17p deletion

MedGen UID:
1842221
•Concept ID:
C5679671
•
Cell or Molecular Dysfunction
Synonyms: Chromosome 17, deletion; Interstitial deletion 17p; Partial monosomy of the short arm of chromosome 17
 
Monarch Initiative: MONDO:0022754
Orphanet: ORPHA261965

Definition

A cytogenetic abnormality that refers to the allelic loss of all or part of the short arm of chromosome 17. [from MONDO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVChromosome 17p deletion

Professional guidelines

PubMed

Incorporating Novel Targeted and Immunotherapeutic Agents in Treatment of B-Cell Lymphomas.
Shah H, Stephens D, Seymour J, Maddocks K
Am Soc Clin Oncol Educ Book 2021 Mar;41:1-18. doi: 10.1200/EDBK_320117. PMID: 33770460
Venetoclax for the Treatment of Chronic Lymphocytic Leukemia.
Eradat H
Curr Hematol Malig Rep 2019 Oct;14(5):469-476. doi: 10.1007/s11899-019-00539-3. PMID: 31512151

Recent clinical studies

Etiology

A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Wiśniewski K, Puła B
Int J Mol Sci 2024 May 11;25(10) doi: 10.3390/ijms25105246. PMID: 38791284Free PMC Article
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.
Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, Walewska R, Furtado M, Preston G, Neilson JR, Pemberton N, Sidra G, Morley N, Cwynarski K, Schuh A, Forconi F, Elmusharaf N, Paneesha S, Fox CP, Howard DR, Hockaday A, Brown JM, Cairns DA, Jackson S, Greatorex N, Webster N, Shingles J, Dalal S, Patten PEM, Allsup D, Rawstron A, Munir T
Lancet Oncol 2023 May;24(5):535-552. doi: 10.1016/S1470-2045(23)00144-4. PMID: 37142374
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum K, Sharman JP, Wierda W, Zhao W, Heerema NA, Luan Y, Liu EA, Dean JP, O'Brien S
Clin Cancer Res 2020 Aug 1;26(15):3918-3927. Epub 2020 Mar 24 doi: 10.1158/1078-0432.CCR-19-2856. PMID: 32209572Free PMC Article
Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
Buccheri V, Barreto WG, Fogliatto LM, Capra M, Marchiani M, Rocha V
Ann Hematol 2018 Dec;97(12):2269-2278. Epub 2018 Oct 12 doi: 10.1007/s00277-018-3503-6. PMID: 30315344
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP
N Engl J Med 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976. PMID: 29562156

Diagnosis

Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion.
Daver NG, Iqbal S, Huang J, Renard C, Lin J, Pan Y, Williamson M, Ramsingh G
Am J Hematol 2023 Aug;98(8):1176-1184. Epub 2023 May 4 doi: 10.1002/ajh.26941. PMID: 37139921
The impact of cytogenetic evolution and acquisition of del(17p) on the prognosis of patients with multiple myeloma.
Salomon-Perzyński A, Bluszcz A, Krzywdzińska A, Spyra-Górny Z, Jakacka N, Barankiewicz J, Borg K, Solarska I, Szpila T, Puła B, Grosicki S, Jamroziak K
Pol Arch Intern Med 2020 Jun 25;130(6):483-491. Epub 2020 Apr 27 doi: 10.20452/pamw.15316. PMID: 32338840
Venetoclax for the Treatment of Chronic Lymphocytic Leukemia.
Eradat H
Curr Hematol Malig Rep 2019 Oct;14(5):469-476. doi: 10.1007/s11899-019-00539-3. PMID: 31512151
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W
N Engl J Med 2019 May 30;380(22):2095-2103. doi: 10.1056/NEJMoa1900574. PMID: 31141631
Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
Buccheri V, Barreto WG, Fogliatto LM, Capra M, Marchiani M, Rocha V
Ann Hematol 2018 Dec;97(12):2269-2278. Epub 2018 Oct 12 doi: 10.1007/s00277-018-3503-6. PMID: 30315344

Therapy

A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Wiśniewski K, Puła B
Int J Mol Sci 2024 May 11;25(10) doi: 10.3390/ijms25105246. PMID: 38791284Free PMC Article
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.
Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, Walewska R, Furtado M, Preston G, Neilson JR, Pemberton N, Sidra G, Morley N, Cwynarski K, Schuh A, Forconi F, Elmusharaf N, Paneesha S, Fox CP, Howard DR, Hockaday A, Brown JM, Cairns DA, Jackson S, Greatorex N, Webster N, Shingles J, Dalal S, Patten PEM, Allsup D, Rawstron A, Munir T
Lancet Oncol 2023 May;24(5):535-552. doi: 10.1016/S1470-2045(23)00144-4. PMID: 37142374
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum K, Sharman JP, Wierda W, Zhao W, Heerema NA, Luan Y, Liu EA, Dean JP, O'Brien S
Clin Cancer Res 2020 Aug 1;26(15):3918-3927. Epub 2020 Mar 24 doi: 10.1158/1078-0432.CCR-19-2856. PMID: 32209572Free PMC Article
Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
Buccheri V, Barreto WG, Fogliatto LM, Capra M, Marchiani M, Rocha V
Ann Hematol 2018 Dec;97(12):2269-2278. Epub 2018 Oct 12 doi: 10.1007/s00277-018-3503-6. PMID: 30315344
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP
N Engl J Med 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976. PMID: 29562156

Prognosis

Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.
Stilgenbauer S, Tausch E, Roberts AW, Davids MS, Eichhorst B, Hallek M, Hillmen P, Schneider C, Schetelig J, Böttcher S, Kater AP, Jiang Y, Boyer M, Popovic R, Ghanim MT, Moran M, Sinai WJ, Wang X, Mukherjee N, Chyla B, Wierda WG, Seymour JF
Blood Adv 2024 Apr 23;8(8):1992-2004. doi: 10.1182/bloodadvances.2023011741. PMID: 38290108Free PMC Article
Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
Cull G, Burger JA, Opat S, Gottlieb D, Verner E, Trotman J, Marlton P, Munoz J, Johnston P, Simpson D, Stern JC, Prathikanti R, Wu K, Novotny W, Huang J, Tam CS
Br J Haematol 2022 Mar;196(5):1209-1218. Epub 2021 Dec 16 doi: 10.1111/bjh.17994. PMID: 34915592Free PMC Article
An Epigenetic Mechanism Underlying Chromosome 17p Deletion-Driven Tumorigenesis.
Chen M, Chen X, Li S, Pan X, Gong Y, Zheng J, Xu J, Zhao C, Zhang Q, Zhang S, Qi L, Wang Z, Shi K, Ding BS, Xue Z, Chen L, Yang S, Wang Y, Niu T, Dai L, Lowe SW, Chen C, Liu Y
Cancer Discov 2021 Jan;11(1):194-207. Epub 2020 Sep 25 doi: 10.1158/2159-8290.CD-20-0336. PMID: 32978226Free PMC Article
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum K, Sharman JP, Wierda W, Zhao W, Heerema NA, Luan Y, Liu EA, Dean JP, O'Brien S
Clin Cancer Res 2020 Aug 1;26(15):3918-3927. Epub 2020 Mar 24 doi: 10.1158/1078-0432.CCR-19-2856. PMID: 32209572Free PMC Article
Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
Buccheri V, Barreto WG, Fogliatto LM, Capra M, Marchiani M, Rocha V
Ann Hematol 2018 Dec;97(12):2269-2278. Epub 2018 Oct 12 doi: 10.1007/s00277-018-3503-6. PMID: 30315344

Clinical prediction guides

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.
Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, Walewska R, Furtado M, Preston G, Neilson JR, Pemberton N, Sidra G, Morley N, Cwynarski K, Schuh A, Forconi F, Elmusharaf N, Paneesha S, Fox CP, Howard DR, Hockaday A, Brown JM, Cairns DA, Jackson S, Greatorex N, Webster N, Shingles J, Dalal S, Patten PEM, Allsup D, Rawstron A, Munir T
Lancet Oncol 2023 May;24(5):535-552. doi: 10.1016/S1470-2045(23)00144-4. PMID: 37142374
The impact of cytogenetic evolution and acquisition of del(17p) on the prognosis of patients with multiple myeloma.
Salomon-Perzyński A, Bluszcz A, Krzywdzińska A, Spyra-Górny Z, Jakacka N, Barankiewicz J, Borg K, Solarska I, Szpila T, Puła B, Grosicki S, Jamroziak K
Pol Arch Intern Med 2020 Jun 25;130(6):483-491. Epub 2020 Apr 27 doi: 10.20452/pamw.15316. PMID: 32338840
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum K, Sharman JP, Wierda W, Zhao W, Heerema NA, Luan Y, Liu EA, Dean JP, O'Brien S
Clin Cancer Res 2020 Aug 1;26(15):3918-3927. Epub 2020 Mar 24 doi: 10.1158/1078-0432.CCR-19-2856. PMID: 32209572Free PMC Article
microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival.
Rossi S, Shimizu M, Barbarotto E, Nicoloso MS, Dimitri F, Sampath D, Fabbri M, Lerner S, Barron LL, Rassenti LZ, Jiang L, Xiao L, Hu J, Secchiero P, Zauli G, Volinia S, Negrini M, Wierda W, Kipps TJ, Plunkett W, Coombes KR, Abruzzo LV, Keating MJ, Calin GA
Blood 2010 Aug 12;116(6):945-52. Epub 2010 Apr 14 doi: 10.1182/blood-2010-01-263889. PMID: 20393129Free PMC Article
Chromosome 17p deletion in human medulloblastoma: a missing checkpoint in the Hedgehog pathway.
De Smaele E, Di Marcotullio L, Ferretti E, Screpanti I, Alesse E, Gulino A
Cell Cycle 2004 Oct;3(10):1263-6. Epub 2004 Oct 3 doi: 10.4161/cc.3.10.1200. PMID: 15467454

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • GTR
      Related information in GTR
    • GTR(Clinical)
      Clinical tests in GTR
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...